Sheng Jiang, NCI/NIH researcher,returned to China at the end of 2007 and is now a researcher and doctoral supervisor of theCAS "Hundred Talents Program"

 Academic Report of Researcher Jiang Sheng, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

author:     Source: China Pharmaceutical University     Hits: 1563     Update Time: 2015-07-07

Report title : Discovery of Novel Class I Histone Deacetylase

Inhibitors through Total Synthesis of Natural Products

Report time : July 10 , 2015 (Friday) 9 :30-11:00

Location of the report: Lecture Hall 307 , Academic Exchange Center, Xuanwumen Campus

Speaker : Jiang Sheng, researcher, Chinese Academy of Sciences "Hundred Talents Program" researcher

Brief introduction : Jiang Sheng, Ph.D., researcher, graduated from China Pharmaceutical University in 1997 and 2000 with a bachelor's degree and a master's degree, respectively, and graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences with a doctorate in 2003 . From 2003 to 2007 , he was engaged in postdoctoral research at the National Cancer Institute of the US Department of Health ( NCI/NIH ) and won the " NIH Fellows Award for Research Excellence ". He returned to China at the end of 2007 and is now a researcher and doctoral supervisor of the "Hundred Talents Program" of the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences . He is also a member of the American Chemical Society, a member of the American Peptide Society, a member of the Chinese Chemical Society, and a senior member of the Chinese Pharmaceutical Association. The research group is mainly engaged in the research of total synthesis of natural products and medicinal chemistry. He has won the 973 project, the major project of "Major New Drug Creation Technology", and the National Natural Science Foundation of China.More than 10 scientific research projects . So far, more than 60 SCI papers have been published in internationally renowned journals such as Angew. Chem. Int. Ed. , J. Med. Chem. , J. Am. Chem.Soc , Org.Lett .

    All teachers and students are welcome to come!

                                       School of Pharmacy, Science and Technology Office

                                            July 7 , 2015 _ _

Jiang Sheng

announcer:Tao ShuyangViews:11101

Personal profiles:

Name :Jiang Sheng Gender :                  male      

Date of Birth :June 14 , 1976 _ _      Specialties : Medicinal Chemistry        

Education : Doctor of Science Professional Technical Position : Professor, Doctoral Supervisor           

E-mail : jiang_shengg @ 126.com    Telephone  (Tel.) : 18688888237

 

learning experience

1993 , 9-1997 , 7 : China Pharmaceutical University, Medicinal Chemistry, Bachelor 

1997 , 9-2000 , 7 : China Pharmaceutical University, Medicinal Chemistry, Master

2000 , 9-2003 , 7 : Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Organic Chemistry, Ph.D.

 

work experience

2003 , 11-2007 , 11 : National Institutes of Health ( NIH ) Cancer Institute ( NCI ); Medicinal Chemistry, Postdoc

2007 , 12-2016 , 12 : Guangzhou Institute of Biology and Health, Chinese Academy of Sciences, medicinal chemistry, doctoral supervisor ,Research group leader.

2017,1 - PRESENT : China Pharmaceutical University, medicinal chemistry, doctoral supervisor ,Research group leader.

 

Main academic achievements, scientific and technological achievements and innovations

 Dr. Jiang Sheng graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2003 with a Ph.D. in organic chemistry. From 2003 to 2007 , he worked as a postdoctoral researcher at the National Cancer Institute ( NCI/NIH ) of the U.S. Department of Health. After returning to China in 2008 , he served as a researcher and doctoral tutor of the "Hundred Talents Program" of Guangzhou Institute of Biomedicine and Health , Chinese Academy of Sciences .Research group leader . Now he is a doctoral supervisor of the Department of Medicinal Chemistry, China Pharmaceutical University .Research group leader. He is also a member of the American Chemical Society, a member of the American Peptide Society, a member of the Chinese Chemical Society, and a senior member of the Chinese Pharmaceutical Association. Employed for several international journals such as J. Med Chem. , Bioorg. Med. Chem. Lett. , Bioorg. Med. Chem. , Eur. J. Med Chem. ,  J. Org. Chem , Organic LettersSpecial reviewer for other journals, and review expert for projects such as the National Natural Science Foundation of China. In recent years, a total of 68 SCI papers have been published, including a series of innovative articles published in the international core journals Angew. Chem. Int. Ed., Organic Letters, Journal of Medicinal Chemistry and Journal of The American Chemical Society . Among them, " Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target " was published in the international publication ACS Chemical BiologyAfter it was published, it aroused strong interest from international peers and was selected as one of the most-accessed articles of the 1st quarter of 2008 .

  At the same time, research on the following projects was completed:

1.   Completed the design and synthesis of the anti-tumor natural product Annonaceous Acetogenins analogs. We used the natural annua lactone- Bullatacin as a template, simplified the double tetrahydrofuran ring into a ethylene glycol diether structure , retained its basic skeleton, and used the concepts of rational drug design, parallel synthesis, fragment assembly, etc. , to effectively establish annua lactone. A library of analog molecules with completely new chemical structures. Among them, the activity of compound AA019 on HT-29 tumor cells was 15 times that of doxorubicin , and it was not toxic to normal cells. In the in vitro test, the compound AA019 can effectively inhibit the growth of  lewis lung cancer in nude mice at an oral dose of 10 mg/kg (compared with the control group, the inhibition rate is more than 60% ). Currently, the compound is in preclinical studies. 

2.    Completed the design and synthesis of natural cyclic peptide ( SFTI-1 ) analogs. Using the binding model of SFTI-1 and protease, a series of novel cyclic peptides were successfully designed and synthesized by computer-aided drug design method. Among them, SFTI-15 had better proteolytic activity ( Ki = 10 nM ) and It has good selectivity and stability. Moreover, further in vivo and in vitro experiments showed that it can effectively inhibit tumor growth.

3.    Completed the design and synthesis of Grb2-SH2 polypeptide inhibitors. Taking G1TE as the lead, the design, synthesis and structure-activity relationship of G1TE analogs were systematically carried out . Among them , the activity of G177 on Grb2-SH2 is more than 1000 times that of G1TE . A batch of Grb2-SH2 antagonists with cell-level tumor growth inhibitory activity were also discovered during development, providing promising pharmacophore patterns and lead compounds for anti-tumor drug candidates.

4.   Completed the design and synthesis of cyclic peptide inhibitors of STAT-3 . This work was published in "ACS Chemical Biology" titled "Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target" and was named the most-accessed article of the first quarter of 2008 by ACS . 1st quarter of 2008 ).

5.   Participated in the University of Michigan as one of the main collaboratorsWang ShaomengProfessor presided over the new anti-tumor drug AT-101 , a broad-spectrum inhibitor of Bcl-2 family proteins, a Spirooxindole class of p53-MDM2 interaction blockers, isoflavone class Bcl-2 family protein inhibitors and protein IAP small molecule inhibitors, etc. Development of antineoplastic drugs.

6.   Completed the design and synthesis of selective inhibitors of histone deacetylation type I enzymes. Among them, the median inhibitory concentration ( IC50 ) of compound Lar-7 on tumor cell lines can reach as low as 1.0 nM ( 26 cell line experiments in vitro showed that the IC50 for multiple series of tumor cells was between 1-40 nM ), and the anti-tumor activity was A similar drug vorinostat ( SAHA ) has been listed abroad 10-100 times; and it is non-toxic to normal cells. The preliminary in vivo pharmacodynamic evaluation and acute toxicity evaluation of Lar-7 also reflect its low toxicity and high efficiency: it is resistant to human prostate cancer Du-145 , human breast cancer MDA-MB-231 and human leukemia imatinib Cells ( T315I ) subcutaneously transplanted tumor in nude mice had obvious inhibitory effect, and the relative tumor proliferation rates ( T/c% , Day-21 ) were 29.64% ,  20% and 37% , respectively . Preliminary acute toxicity test showed that the LD50 of Lar-7 in Kunming mice( 256.2 mg/kg ) is far greater than that of the similar drug Romidepsin ( 3.6 mg/kg ) that has been marketed abroad, showing extremely low toxicity. Currently, the compound is in preclinical studies.

7.   Design and synthesize a new biotin-labeled cyclic peptide compound , and successfully  " catch " a new protein  "r-catenin" with the labeled compound . We verified and found that this protein is a key protein in the self-renewal of leukemia cancer stem cells , and the compounds we designed can effectively overcome the problem of imatinib resistance by inhibiting this protein.

8.   Completed the design and synthesis of multiple inhibitors of EGFR, Her-2 and HDC . Among them, the median inhibitory concentration ( IC50 ) of compound JSNMPT-17 on multiple series of tumor cells is between 1-10 nM , and its anti-tumor activity is about 50 times that of a foreign phase II clinical drug ( CUC-101 ) . Currently , the in vivo pharmacodynamic evaluation of JSNMPT-17 is in progress.

9.   Completed the total synthesis of 7 natural products , they are Largazole, FK-228, Argyrins A and E, (-)-Norsecurinine, (+)-Niruroidine and Flueggine A.

10.  Completed the design and synthesis of IDO inhibitors. Among them, the antitumor activity of the compound JQIDO-003 is comparable to that of foreign phase II clinical drugs. Currently , the in vivo pharmacodynamic evaluation of  JQIDO-003 is ongoing.

 

Major scientific research projects hosted in the past five years

 

serial number	Subject name	Numbering	host or participate	Start and end time	expenses ( 10,000 yuan )	category
1	Synthesis of Compounds and Derivatives with Stem Cell Regulation Activity	2009CB940904	host	2009.1- 2013.12	6.9 million	973 project sub-topics
2	Study on the simplified analog AA-005 of annua lactone as an anticancer drug	2009ZX09103-101	host	2009.1- 2010 ．12	1.26 million	National New Drug Innovation Major Project
3	Structure-activity relationship and antitumor activity of histone deacetylase inhibitor Lar-7	21172220	host	2012.1- 2015.12	600,000 _	National Natural Science Foundation of China surface item
4	Total Synthesis of Argyrin A	20972160	host	2010.1- 2012.12	350,000 _	National Natural Science Foundation of China surface item
5	Proteolytic enzyme cyclic peptide inhibitor and its antitumor activity	20802078	host	2009.1- 2011.12	180,000 _	National Natural Science Foundation of China Youth Fund
6	Design and Synthesis of Cyclic Peptide Inhibitors of Proteolytic Enzymes	NNCAS-2008-8	host	2009.1- 2010 ．12	500,000 _	Novartis Nordisk - Chinese Academy of Sciences Joint Fund
7	Proteolytic enzyme inhibitors and their antitumor activity	KSCX2-YW-R-215	host	2010.1- 2010.12	200,000 _	Important direction project of knowledge innovation project of Chinese Academy of Sciences
8	Design and synthesis of small molecule inhibitors of proteolytic enzymes	8151066302000008	host	2009.1- 2011.12	50,000 _	Natural Science Foundation of Guangdong Province
9	Total Synthesis of Flueggines A and B	21472191	host	2015.1- 2018.12	900,000 _	National Natural Science Foundation of China surface item
10	Study on AA-005 as Anticancer Drug	2013A022100019	participate	2015.1- 2017.12	1.5 million	Guangdong Province New Drug Creation Project
11	Construction of Molecular Probes for Histone Deacetylation Type I Enzymes and Research on Early Diagnosis and Treatment	2016A050502036	host	2016.1- 2018.12	500,000 _	Guangdong Province International Cooperation Project
12	Molecular probes of histone deacetylation type I enzymes as early diagnosis and treatment of tumors		host	2017.5- 2020.4	1 million	Guangzhou Industry-University-Research Collaborative Innovation Major Project

 

Invited report

 

1. Sheng Jiang  (invited speaker), “Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, National Cancer Institute 2015 (2015,10,20Fredercik, US).

2. Sheng Jiang  (invited speaker), “Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, Chinese Pharmaceutical University 2015 (2015,7,10Nanjing, China).

2. Sheng Jiang  (invited speaker), "Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products", The 4th Natural Product Total Synthesis - Youth Symposium (2015,7, Chengdu , China).

3.  Sheng Jiang  (invited speaker), "Discovery of Novel Class I Histone Deacetylase Inhibitors", 10th National Natural Organic Chemistry Conference of Chinese Chemical Society  (2014,11 Guangzhou, China).

4.  Sheng Jiang  (invited speaker), “Design, Synthesis and Biological Evaluation of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, 2012 ( Shanghai , China).

5. Sheng Jiang  (invited speaker), “From Total Synthesis of Natural Products to Discovery of New Histone Deacetylase Inhibitors”, The 4th China-Thailand Workshop on Natural Products and Drug Discovery, Trang Province, Thailand, November 26-30, 2012

6. Sheng Jiang  (invited speaker), “Discovery of New Histone Deacetylase Inhibitors”, The 28th CCS National Congress (2012,Chendu, China)

7. Sheng Jiang  (invited speaker), “Design and synthesis New Histone Deacetylase 1 (HDAC1) inhibitors as potential anticancer drugs”, National Cancer Institute, Frederick, MD, 2010

8. Sheng Jiang  (invited speaker), “Total Synthesis of Largazole and its analogues potential anticaner drugs”, The 5 th  CCS National Congress on organic chemistry (2009, Xian,China).

9. Sheng Jiang  (invited speaker), “Potent antagonists of the Grb2-SH2 domain: Not relying on phosphotyrosine mimics”, Chinese Pharmaceutical University 2006 (2006,Nanjing, China).

 

10. Sheng Jiang ,  et al. “Potent antagonists of the Grb2-SH2 domain: Not relying on phosphotyrosine mimics”, 232 th  American Chemical Society Meeting (9/10-9/14, 2006).

11. Sheng Jiang ,  et al. “Synthesis and Evaluation of Analogs of SFTI-1, Potent Inhibitors of the Type II Transmembrane serine protease, Matriptase”, 230th American  Chemical Society Meeting (8/28-9/1, 2005).

12. Sheng Jiang ,  et al. “Synthesis of Symmetrical Dimeric Dicarboxylic Acid Linked Peptides on Solid support”, 19th American  Peptide Symposium (6/18-23, 2005).

13. Sheng Jiang , et al. “First Chemical Synthesis of Butenolide2", The 2 nd  CCS National Congress on organic chemistry and the 1 st  CCS National Congress on Chemical Biology (2002, China).

 

Awards and Honors:

2011  The 14th Chinese Pharmaceutical Association - Servier Youth Medicinal Chemistry Award

20 10     Hundred Talent Award

20 07 NIH Fellows award for the Research Excellence            

1996      Excellent Student  Scholarship

 

Patent

 

1.   “Synthesis and application of ether bond modified chiral annonaceous acetogenins compound”

Licensed to Shanghai Institute of Organic Chemistry

Inventors: ZJ Yao, YL Wu and S. Jiang.

Patent No. CN1477103

2.   “Method for synthesis of largazole and its analogs as antitumor agents.”

Inventors: S. Jiang, G. Zhou, B. Yin, X. Zeng, and Z. Hu.

Patent No. CN 101781321

3.  “Annonaceous acetogenins analogs as antitumor agents and their preparation, pharmaceutical compositions and use in the treatment of cancer”

Inventors:  S. Jiang,  ZJ Yao, G. Zhou, Q. Xiao, Y. Liu

Patent No. CN 101982464

4.   “Preparation of cyclopeptides as histone deacetylase inhibitors”

Inventors: S. Jiang,  S. Li, Y. Yao, F. Zhang, Y. Chao, H. Ye, M. Chen 

CN Patent Serial No. CN102391359

5.   “Preparation of triazole compounds as histone deacetylase inhibitors.”

Inventors: S. Jiang, Z.Tu, Y. Yao, C. Liu, H. Yao, X. Xue,

Patent No. CN 102311398

6.  “Process for preparation of FK228”

Inventors:  S. Jiang,  J. Xu, S. Li, H. Yao, X. Zeng,   Y. Yao,

Patent No. CN 102276689

7.        “Quinoxalinyl bis(N-oxide) derivatives and their application as ligands in Cu-catalyzed CO coupling reaction”

Inventors: Z. Yao,  S. Jiang, 

Patent No. CN 102060790

8.        “Quinoline derivative-N-oxide ligands, their preparation method and application in NC coupling”

Inventors:  Z. Yao,   S. Jiang, 

Patent No. CN 101899003

9.                  “Method for preparing epichlorohydrin tetramer and its reaction with   formaldehyde derivative”

      Inventors:  D. Zhang, J. Su, S. Jiang, 

Patent No. CN 103864727

10.    “Preparation of largazole analog compounds as antitumor agents”

      Inventors: S. Jiang,  Z. Tu, X. Li, Y. Yao, Y. Qiu

Patent No. CN 103601742

11.   “13-membered cyclic peptide as histone deacetylase inhibitor and its preparation”

    Inventors: H. Xiang, G. Wang, S. Jiang,  Z. Tu,

Patent No. CN 103232474

12.  "Preparation of N-containing heterocyclic derivatives as histone deacetylase I inhibitor"

Inventors: S. Jiang ,  Z. Tu, Q. Sun, C. Liu, Y. Yao, Y. Qiu,

Patent No. CN 103086971

13. “Preparation of 3-(pyridin-3-yl)acrylamide derivatives as nicotinamide phosphoribosyltransferase inhibitors useful for the treatment of cancer”

   Inventors: S. Jiang,  Z. Tu, D. Zheng, D. Qin, J. Bai, X. Qin, Y. Yao, Y. Liu, Y. Qiu, J. Chen

    Patent No. CN 104557863/PCT090572

 

  

 

Representative papers since engaging in scientific research

1.        J. Bai, , C. Liao, D. Qin, Y. Liu, X. Qing, J. Chen, Z. Li, Z. Tu, S. Jiang.* Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising In Vitro and in Vivo Antitumor Activities. J. Med. Chem . 2016 , 59 , 5766-5779.

2.       N. Ma, Y. Luo, Y. Wang, C. Liao, W.-C. Ye*, S. Jiang* .Selective histone deacetylase inhibitors with anticancer activity. Curr. Top. Med. Chem. 2016 , 16 , 415-426. 

3.       Y. Jin, Y. Yao, L. Chen, X. Zhu, B. Jin, Y. Shen, J. Li, X. Du, Y. Lu, S. Jiang* , J. Pan*.Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with imatinib.  Theranostics . 2016 , 6, 1947-1962.

4.       Y. Yao,Z. Tu,C. Liao, Z. Wang, S. Li, H. Yao, Z. Li, S. Jiang* .Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro Selectivity for Cancers Cells and in Vivo Antitumor Activities.  J. Med. Chem . 2015 , 58 , 7672-7680.

5.       Y. Yao,Z. Li, Y. Qiu, J. Su, S. Jiang* .Unprecedented reactions: from epichlorohydrin to epoxyglycidyl substituted divinyl ether and its conversion into epoxyglycidyl propargyl ether .  Scientific Reports .  2015, 5 , srep14231.

6.       N. Ma, Y. Wang, B. Zhao, W.-C. Ye*, S. Jiang* .The application of click chemistry in the synthesis of agents with anticancer activity. Drug Design, Development and Therapy . 2015 , 50 , 1585-1599. 

7.        J. Zhang, H. Zhou, S. Jiang,  J. Jin, W. Li, W. Wang, S. Su. AA092, an annonaceous acetogenin mimetic, attenuates angiogenesis in a mouse model of inflammation-induced corneal neovascularization. International Immunopharmacology . 2015 , 28 , 997-1002.

8.       Y. Zhou, G. Hou, S. He, Z. Xiao, H. Xu, Y. Qiu,S. Jiang, H. Zheng, Z. Li. Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells. CNS Neuroscience & Therapeutics . 2015 , 21 , 558-567.

9.       N. Ma, Y. Yao, B.-X. Zhao, Y. Wang, W.-C. Ye*, S. Jiang* .Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun . 2014 , 50 , 9284-9287. 

10.    X. Zhu, L. Chen, S. Jiang , C. Chen, Y. Yao, D. Chen, H. Xue, J. Pan * .PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biology & Therapy . 2014 , 15 , 119-127. 

11.    J. Su, Y. Qiu, S. Jiang*,  D. Zhang*.New Ligands for Copper-Catalyst C[n.63743]N Coupling Reactions at Gentle Temperature. Chinese Journal of Chemistry . 2014 , 32(8) , 685-688.

12.    J. Su, Y. Qiu, K. Ma, Y. Yao, Z. Wang, X. Li, D. Zhang, Z. Tu, S. Jiang* .Design, synthesis, and biological evaluation of larga zole derivatives: alteration of the zinc-binding domain. Tetrahedron. 2014 , 70 , 7763-7769.

13.     H. Zhou, S. Jiang,  J. Chen, X. Ren, J. Jin, SB Su*. Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization. European Journal of Pharmacology. 2014 , 740 , 619-626.

14.    H. Zhou,S. Jiang,  J. Chen, SB Su*. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization.Can. J. Physiol. Pharmacol. 2014 , 92 , 879-885.

15.    Y. Liu, Y. Liu, Z. Liu, G. Zhou, Z.-J.Yao* , S. Jiang* . Identification of novel bivalent mimetics of annonaceous acetogenins via a scaffold-hopping strategy.  Bioorg. Med. Chem. Lett. 2014 , 24 , 1650-1653.

16.    Y. Liu, Q. Xiao, Y. Liu, Z. Li, Y. Qiu, G.-B. Zhou, Z.-J.Yao, S. Jiang* . Biological evaluation of new mimetics of annonaceous acetogenins: alteration of right scaffold by click linkage with aromatic functionalities. Eur. J. Med. Chem . 2014 , 78 , 248-258.

17.     Y. Yao, C. Liao, Z. Li, Z. Wang, Q. Sun, C. Liu, Z. Tu * , S. Jiang* . Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted- Pyrazole Derivatives as New Class I and IIb Histone Deacetylase Inhibitors.  Eur. J. Med. Chem . 2014 , 86 , 639-652. 

18.    Y. Zhao, X. Fang, Y. Wang, J. Zhang,  S. Jiang , Z. Liu, Z. Ma, L. Xu, E. Li, K. Zhang. Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor. Current Pharmaceutical Design . 2014 , 20 , 1866-1873.

19.     D. Zou, Y. Qiu, Z. Tu, C. Liao, J. Luo, Q. Meng, R. Yao, Z. Li, S. Jiang* .. Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. ScienceChina: Chemistry . 2014 , 57 , 823-832.

20.    Q. Meng, F. Li,S. Jiang, Z. Li*.Novel 64 Cu-labeled CUDC-101 for in vivo PET Imaging of histone deacetylases. ACS Medicinal Chemistry Letters . 2013 , 4, 858-862.

21.    L. Wu, Z. Wen, Y. Qiu, X. Chen, H. Chen, M. Wei, Z. Liu, S. Jiang*, G. Zhou*.Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells; ACS Medicinal Chemistry Letters . 2013 , 4,  921-926.

22.    Y. Yao, H. Yao,S. Jiang*, X. Xue*.Progress in clinical study of histone deacetylase inhibitors as anticancer agents; Chinese J New Drugs . 2013 , 22  (3), 1-7.

23.    Q. Sun , Y. Yao,  C. Liu, H. Li, H. Yao, X. Xue, J. Liu, Z. Tu * , S. Jiang* . Design, Synthesis, and Biological Evaluation of Novel Histone Deacetylase 1 Inhibitors through click chemistry.  Bioorg. Med. Chem. Lett. 2013 , 23, 3295-3299.

24.    X. Li, Z. Tu, H. Li, C. Liu, Z. Li, Q. Sun, Y. Yao, J. Liu, S. Jiang* .Biological evaluation of new largazole analogues: Alteration of macrocyclic scaffold with Click chemistry; ACS Medicinal Chemistry Letters . 2013 , 4 , 132-136.

25.    Y. Qiu, W. Jia, Z. Yao, F. Wu, S. Jiang *. 2-Carbomethoxy-3-hydroxyquinoxaline-di- N - oxide as a novel ligand for the copper-catalyzed coupling reaction of phenols and aryl halides.  Organic & Biomolecular Chemistry. 2013 , 11, 1502-1510.

26.    Yang, Mei; He, Jiangbo; Cheng, Yongxian; Jiang, Sheng* . Synthesis of 3-[(Z)-pentadec-8-enyl]catechol and its anti-angiogenesis activity. Chinese Journal of Organic Chemistry . 2013 , 33(6), 1319-1325.

27.    D. Che, K. Yang, H. Xiang,S. Jiang* . New ligands for copper-catalyzed CN coupling reactions with aryl halides; Tetrahedron Letters . 2012 , 53, 7121-7124.

28.    Y. Liu, X. Cheng, L. Guo, C. Mao, Y. Chen, H. Liu, Q. Xiao, S. Jiang , Z. Yao, G. Zhou. Identification of an annonaceous acetogenin mimetic, AA005 , as an AMPK activator and autophagy inducer in colon cancer cells; PLoS One . 2012 , 7 , e47049.

29.    K. Su, Y. Qiu,; Y.Yao,; D. Zhang, S. Jiang* . 8-hydroxyquinolin-N-oxide-promoted copper-catalyzed CS cross-coupling of thiols with aryl iodides; Synlett . 2012 , 23, 2853-2857.

30.     Q. Xiao, Y. Liu, Y. Qiu, G. Zhou, C. Mao, Z. Li, Z.-J. Yao * , S. Jiang* . Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part; J. Med. Chem. 2011 , 54 , 525-533.

31.    K. Yang, Y. Qiu, Z. Li, Z. Wang, S. Jiang* , Ligands for Copper-Catalyzed C-N Bond Forming Reactions with 1 Mol% CuBr as Catalyst.  J. Org. Chem , 2011 , 76, 3151-3159.

32.     Y. Qiu, Y. Liu, K. Yang, W. Hong, Z. Li, Z. Wang, S. Jiang*. New Ligands That Promote Cross-Coupling Reactions between Aryl Halides and Unactivated Arenes.  Org. Letters , 2011 , 13 , 3556-3559 .

33.     K. Yang, Z. Li, Z. Wang, S. Jiang* . Highly Efficient Synthesis of Phenols by Copper-Catalyzed Hydroxylation of Aryl Iodides, Bromides, and Chlorides.  Org. Letters , 2011 , 13, 4340-4343 .

34.     W. Wu, Z. Li, G. Zhou,  S. Jiang* . Total synthesis of argyrins A and E.  Tetrahedron. Lett . 2011 , 52 , 2488-2491.

35.    Z. Yao, X. Zeng, W. Yi,S. Jiang* . Stereoselective Synthesis of (S,E)-2-(trimethylsilyl)ethyl 3-hydroxy-7-(tritylthio) hept-4-enoate. Letters in Organic Chemistry, 2011 , 8 , 66-69.

36.    Q. Xiao, Y. Liu, Y. Qiu, Z. Yao, G. Zhou, Z.-J.Yao* , S. Jiang* . Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities.  Bioorg. Med. Chem. Lett. 2011 , 21 , 3613-3615.

37.     S. Li, H. Yao, J. Xu * , S. Jiang* . Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors. Molecules , 2011 , 16 , 4681-4694.

38.    L. Johannessen, J.Remsberg, V. Gaponenko, KM Adams, JJ Barchi, SG Tarasov, S. Jiang ,   NI Tarasova. Peptide Structure Stabilization by Membrane Anchoring and its General Applicability to the Development of Potent Cell-Permeable Inhibitors. ChemBioChem. 2011 , 12 , 914- 921.

39.     Z. Yao, Y. Xu, M. Zhang, S. Jiang , MC Nicklaus, C. Liao. Discovery of a novel hybrid from finasteride and episteride as5a-reductase inhibitor.  Bioorg. Med. Chem. Lett, 2011 , 21 , 475-478.

40.    W. Hong, Y. Qiu, Z. Yao, Z. Wang,S. Jiang* . Palladium-Catalyzed Direct C–H Arylation of Unactivated Arenes with Aryl Halides.  Tetrahedron. Lett . 2011 , 52, 4916-4919.

41.    X. Zeng, W. Huang, Y. Qiu, S. Jiang *. Efficient Copper-Catalyzed Synthesis of Anilines by Employing Aqueous Ammonia.  Organic & Biomolecular Chemistry. 2011 , 9, 8224-8227.

42.    Y. Xu, F. Wu, Z. Yao, S. Jiang . Synthesis of quinoxaline 1,4-di-N-oxide analogues and crystal structure of 2-carbomethoxy-3-hydroxyquinoxaline-di-N-oxide. Molecules , 2011 ,  6894-6901 .

43.     X. Zeng, B. Yin, Z. Hu, C. Liao, Z. Li, G. Zhou*, S. Jiang * .Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells.  Orgainc. Lett . 2010 , 12 , 1368-1371.

44.     J. Zheng, B. Yin, W. Huang, X. Li, H. Yao, Z. Liu, S. Jiang *. Efficient and selective cleavage of the t -butoxycarbonyl group from di- t -butylimidodicarbonate using catalytic bismuth (III) bromide in acetonitrile. Tetrahedron. Lett . 2009 , 50 , 5094-5097.

45.     S. Jiang* , C. Liao, L. Bindu, B. Yin, KW Worthy, RJ Fisher, TR Burke, Jr., MC Nicklaus, PP Roller. Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg. Med. Chem. Lett.2009 , 19 , 2693-2698.

46.    Z. Nikolovska-Coleska, J. Meagher, S. Jiang,  C. Yang, S. Qiu, PP Roller, J. Stuckey, S. Wang. Interaction of a Cyclic, Bivalent Smac Mimetic with the X-Linked Inhibitor of Apoptosis Protein. Biochemistry . 2008 , 47 , 9811-9824.

47.     S. Jiang *, Z. Li, K. Ding, PP Roller. Recent Progress of Synthetic Studies to Peptide and Peptidomimetic Cyclization. Current Organic Chemistry. 2008 , 12 , 1502-1542.

48.     Z. Nikolovska-Coleska, J. Meagher, S. Jiang, SA Kawamoto, W. Gao, H. Yi, D. Qin, PP Roller, J. Stuckey, S. Wang. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal Biochem. 2008 , 374 , 87-98.

49.     OA Timofeeva, V. Gaponenko, SJ Lockett, SG Tarasov, S. Jiang , CJ Michejda, AO Perantoni, NI Tarasova. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target.  ACS Chem Biol. 2007 , 2 , 799-809.

50.     S. Jiang, P. Li, SL Lee, CY Lin, YQ Long, MD Johnson, RB Dickson, PP Roller. Design and Synthesis of redox stable analogues of Sunflower Trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of Matriptase. Orgainc. Lett . 2007 , 9 , 9-12 .

51.    HX. Liu, GR. Huang, HM Zhang, S. Jiang, J.-R. Wu, Z. -J. Yao.  A Structure-Activity Guided Strategy for Fluorescent Labeling of Annonaceous Acetogenin Mimetics and their Application in Cell Biology .ChemBioChem.2007 , 8 , 172-177.

52.     P. Li,  S. Jiang,  SL Lee, CY Lin, MD Johnson, CJ Michejda, RB Dickson, PP Roller.Synthesis and evaluation of analogs of SFTI-1, potent inhibitors of the Type II transmembrane serine protease, Matriptase. J. Med. Chem. 2007 , 50, 5976-5983.

53.    P. Li, S. Jiang,  PCStephanie, O. Lyn, DN Krag,PP Roller. Design and Synthesis of Water-Soluble Conjugates of Paclitaxel to Extracellular Doma in of ErbB2-Recognizing Peptide. Biopolymers. 2007 , 87,  225 -230.

54.    H. Sun, Z. Nikolovska-Coleska, J. Lu, J. Meagher, C. Yang, S. Qiu, Y. Tomita, Y. Ueda, S. Jiang,  Krajewski, PP Roller, JA Stuckey, S.Wang.Design, Synthesis and Characterization of A Potent, Non-Peptide, Cell-Permeable, Bivalent Smac Mimetic that Concurrently Targets both the BIR2 and BIR3 Domainsin XIAP. J. Am. Chem. Soc. 2007 , 129, 15279-15294. 

55.    GZ Tang, CY Yang, Z. Nikolovska-Coleska, J. Guo, S. Qiu, RX Wang, W. Gao, GP Wang, J. Stuckey, K. Krajewski, S. Jiang,  PP Roller, S. Wang .Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.  J. Med. Chem.2007 , 50, 1723-1726.

56.    GZ Tang, K. Ding, Z. Nikolovska-Coleska, CY Yang, S. Qiu, S. Shangary, RX Wang, J. Guo, W. Gao, J. Meaghe, J. Stuckey, K. Krajewski, S . Jiang,  PP Roller, S. Wang.Structure-Based Design of Flavonoid Compounds As a New Class of Small-Molecule Inhibitors of the Anti-apoptotic Bcl-2 Proteins. J. Med. Chem.2007 , 50 , 3163-3166.

57.    J. Chen, Z. Nikolovska-Coleska, CY Yang, C. Gomez, W. Gao, K. Krajewski, S. Jiang , P.  P. Roller, S. Wang. Design and synthesis of a new, conformationally constrained , macrocyclic small-molecule inhibitor of STAT3 via 'click chemistry'.Bioorg. Med. Chem. Lett.2007 , 17 , 3939-3942.

58.     S. Jiang,  P. Li, CC Lai, JA Kelley,P. Roller.Design and Practical Synthesis of Fully Protected analogs of L-γ-Carboxyglutamic Acid.  J. Org. Chem. 2006 , 71 , 7307-7314.

59.     S. Jiang,  P. Li, M. Peach, RJ Fisher, TR Burke, M. Nicklaus, PP Roller. Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.  Biochem. Biophys. Res. Commun. 2006 , 349 , 497-503.

60.     S. Jiang,  CC Lai, JA Kelley, PP Roller. A   Practical Synthesis of Fully Protected L-γ-Carboxyglutamic Acid (L-Gla).  Tetrahedron. Lett . 2006 , 47, 23-25.

61.    GP Wang,  Z. Nikolovska-Coleska, CY Yang, RX Wang, GZ Tang, J. Guo, S.    Shanggary, S. Qiu, W. Gao, DJ Yang, J. Meagher, J. Stuckey, K. Krajewski , S. Jiang,  PP Roller, HO Abbaan, Y. Tomita, S. Wang. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.  J. Med. Chem.2006 , 49, 6139-6142.

62.    Y. Zhao, S. Jiang,  YW Guo, Z.-J.Yao.  Synthesis of two naturally occurring 4-hydroxylated butenolides with PTP1B inhibitory activity. Chinese. J. Chem . 2005 , 23 , 173-175.

63.     S. Jiang , Y. Li, XG Chen, TS Hu, YL Wu, Z.-J. Yao. Parallel fragment assembly strategy towards multiple-ether mimicry of anticancer annonaceous acetogenins.  Angew. Chem. Int. Ed . 2004 , 43 , 329-334. 

64.    GR Huang, S. Jiang , YL Wu, ZJ Yao, JR Wu. Induction of cell death of gastric cancer cells by a modified compound of the annonaceous acetogenin family.  Chem BioChem 2003 , 4 , 1216-1221.

65.    BB Zeng, YK Wu, S. Jiang , Q. Yu, ZJ Yao, Z. Liu, H. Li, Y. Li, X. Chen, YL Wu. Studies on Mimicry of Naturally occuring Annonaceous Acetogenins: Non-THF Analogues Leading to Remarkable Selective Cytotoxicity Against Human Tumor cells.Chem. Eur. J. 2003 ,  9 , 282-290.

66.     S. Jiang , YL Wu, ZJ Yao. Synthesis of A Mimicking Hybrid of Annonaceous acetogenin with Steroid for considerable Antitumor Activity Investigation.Chinese J. Chem. 2002 , 20 , 1393-1400.

67.     S. Jiang , YL Wu, ZJ Yao.  First Synthesis of Mosquito larvicidal Butenolides I and II.  Chinese J. Chem. 2002 , 20 , 692-696.

68.        S. Jiang , Z. Liu, G. Sheng, BB Zeng, XG Cheng, YL Wu, ZJ Yao. Mimicking of Annonaceous Acetogenins: Enantionselective Synthesis of a (4R)-Hydroxy Analog Having Potent Antitumor Activity.  J. Org. Chem , 2002 , 67 , 3404-3408.

• guide students

Jiang Shengnan Han doctoral supervisor Guangzhou Institute of Biomedicine and Health
Email: jiang_sheng@gibh.ac.cn
Tel: 020-32015318
Mobile number:
Mailing address: No. 190 Kaiyuan Avenue, Luogang District, Guangzhou
Postcode : 510530

Research areas

1. Rational design, synthesis and structure-activity relationship research of active small molecules and polypeptide compounds targeting specific pathogenic genes.
2. Total synthesis of natural products with antitumor activity and discovery of new leading drugs.

Admissions Information

   

Admissions Major

100701 - Medicinal Chemistry

Admissions direction

Design and Synthesis of
Anticancer Drugs Design and Synthesis of Anticancer Drugs

Education background

   

Education

-- Postgraduate

Bachelor of Science

-- PhD

study abroad

2003, 11~ 2007, 11 National Cancer Institute, National Institutes of Health (NIH, NCI), Postdoctoral fellow

work experience

2007, 11 ~ present, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

Publication information

   

Published papers

(1) Total synthesis of argyrins A and E, Tetrahedron. Lett., 2011, corresponding author
(2) Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities, Bioorg. Med. Chem. Lett., 2011, corresponding author
(3) Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part, J. Med. Chem, 2011, corresponding author
(4) Ligands for Copper Catalyzed CN Bond Forming Reactions with CuBr as Catalyst, J. Org Chem, 2011, corresponding author
(5) Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors, Molecules, 2011, corresponding author
(6) New Ligands That Promote Cross-Coupling Reactions between Aryl Halides and Unactivated Arenes, Org. Letters, 2011, corresponding author
(7) Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells, Organicc. Lett., 2010, corresponding author

Research activities

   

scientific research projects

Presided over the National Natural Science Foundation of China, the 973 sub-project, and the National New Drug Creation Major Project.

guide students

Currently guiding students

Xiao Qicai Master student 077901-Medicinal chemistry  

Wu Wenbin Postgraduate 077901-Medicinal Chemistry  

Liu Yanghan Postgraduate 077901-Medicinal Chemistry  

Bing Sun, a NIH researcher and director of the Pasteur Institute in Shanghai, Chinese Academy of Sciences,was selected in the immunology major of the "Hundred Talents Program" of the Chinese Academy of Sciences.

 

• Sun Bing
• Researcher, research group leader, doctoral supervisor
• E-mail:  bsun@sibs.ac.cn

Personal profile:

He received his Ph.D. from Shanghai Second Medical University in 1991. From February 1994 to January 1999, he was engaged in postdoctoral and senior visiting scholar research at the National Institutes of Health (NIH), and from January 1999 to present in Biochemistry, Chinese Academy of Sciences With the Institute of Cell Biology, the Molecular Immunology Department was established, and he served as the research group leader and doctoral tutor. From April 2006 to December 2016, he was the director of the Pasteur Institute in Shanghai, Chinese Academy of Sciences.


　　Researcher Sun Bing has long been engaged in the research on the differentiation mechanism of T helper cells (Th), and explored the mechanism of action of different Th cell subsets in autoimmune diseases. He is currently a member of the American Association of Immunologists (AAI), the vice chairman of the Chinese Society of Immunology, and the executive director of the Chinese Society of Cellular Science. In 2003, he was awarded the support of the National Research Fund for Distinguished Young Scholars.


research direction:
Research on the differentiation mechanism of Th cells and their role in autoimmune diseases
research work:
　　1. Allergic Asthma


　　In recent years, due to air pollution (such as smog, etc.), the incidence of asthma has continued to rise, and the existing methods cannot be effectively controlled. Studies have shown that allergens can cause damage to lung mucosal epithelial cells, and further activate type II lymphoid immune cells (Innate lymphoid type 2 cells: ILC2) by releasing inflammatory cytokines such as IL-25, IL-33 and TSLP. ILC2 cells can secrete IL-5 and IL-13, and at the same time, under the action of allergens, they can drive naive CD4+ T cells to differentiate into Th2 cells, and finally induce asthma disease. The laboratory has been engaged in the research on the molecular mechanism of Allergic Asthma disease for a long time, and currently focuses on the function research and interaction regulation mechanism of Th2 and ILC2 two immune cells. Using a mouse model of allergic asthma, combined with clinical data from asthma patients, the study




How new transcriptional regulators, epigenetic molecules and metabolic signaling pathways and products regulate the functions of these cells and their regulatory mechanisms on the pathogenesis of asthma provide new ideas and strategies for the development of new drugs and the prevention and treatment of asthmatic diseases.
 


　　2. Cancer Immunotherapy


　　Since 2011, a variety of immune checkpoint blockers and targeted immune cell drugs have achieved good clinical results in the treatment of various tumors, and have developed into the most potential cancer treatment strategies currently recognized. The marketed immunotherapy methods only show good results in some patients, while drug resistance and poor prognosis appear in most tumor patients, which makes tumor immunotherapy have certain limitations. Relying on a mature mouse experimental system and patient samples provided by clinical hospitals, this study focused on exploring the important regulatory roles of CD8+ and Treg cells in the formation of Lung Cancer, and selected specific targets.




Use the laboratory's perfect single-cell technology to prepare antibodies and drug research and development technology systems, prepare tumor-targeted Treg and enhance the function of CD8+ cells, and then develop new antibodies with anti-tumor effects, evaluate the anti-tumor effects of new antibodies in vivo and in vitro, develop New drugs provide new regimens and strategies for antibody immunotherapy against Lung Cancer.
 


　　3. Antibody drug discovery


　　The laboratory has nearly 20 years of antibody research history, and has a complete antibody research platform. The laboratory has established a complete single-cell RT-PCR technology for the preparation of fully human monoclonal antibodies, especially for infectious diseases, which can quickly obtain therapeutic antibody drug candidates. At the same time, in response to the problem of immune tolerance in some antigen-immunized mice and the inability to obtain monoclonal antibodies, the immune tolerance can be broken by using the two mechanisms of somatic high-frequency mutation and somatic gene replacement in rabbit immune cells. The laboratory has established a technique for preparing rabbit monoclonal antibodies based on single-cell RT-PCR. Our technical system covers key steps in antibody drug development such as target discovery and validation, antibody preparation and functional evaluation, and intellectual property management. The laboratory has successfully developed and transformed projects such as HCV broad-spectrum neutralizing fully human antibodies. The laboratory is currently focusing on diseases such as asthma and tumors. Carry out basic and clinical research to develop innovative antibody drugs.


Representative works:
Chunyan Yi, Xiaoyu Sun , Jing Ye, Longfei Ding , Meiqin Liu , Zhuo Yang , Xiao Lu , Yaguang Zhang , Liyan Ma , Wangpeng Gu , Aidong Qu , Jianqing Xu , Zhengli Shi *, Zhiyang Ling* and Bing Sun *;Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cellular & Molecular Immunology , 2020, 17:621–630.
Yaguang Zhang, Xuezhen Li, Zhongguang Luo, Liyan Ma, Songling Zhu, Zhishuo Wang, Jing Wen, Shipeng Cheng, Wangpeng Gu, Qiaoshi Lian, Xinhao Zhao, Weiguo Fan, Zhiyang Ling, Jing Ye, Songguo Zheng, Dangsheng Li, Hongyan Wang , Jie Liu*, Bing Sun* ; ECM1 is an essential factor for the determination of M1macrophage polarization in IBD in response to LPS stimulation, PNAS, 2020, 117(6): 3083-3092.
Weiguo Fan, Tianhui Liu, Wen Chen, Seddik Hammad, Thomas Longerich, Ingrid Hausser, Yadong Fu, Nan Li, Yajing He, Cui Liu, Yaguang Zhang, Qiaoshi Lian, Xinhao Zhao, Chenghua Yan, Li Li, Chunyan Yi, Zhiyang Ling , Liyan Ma, Xinyan Zhao, Hufeng Xu, Ping Wang, Min Cong, Hong You, Zhihong Liu, Yan Wang, Jianfeng Chen, Dangsheng Li, Lijian Hui, Steven Dooley * , Jinlin Hou * , Jidong Jia * and Bing Sun * ( 2019). ECM1 Prevents Activation of Transforming Growth Factor beta, Hepatic Stellate Cells, and Fibrogenesis in Mice. Gastroenterology. 2019;157:1352–1367.
Fang Yu*, Sharma Suveena, Dragana Jankovic, Rama Krishna Gurram, Pan Su, Gangqing Hu, Rao Li, Sadiye Rieder, Keji Zhao, Bing Sun *, Jinfang Zhu*; The transcription factor Bhlhe40 is a switch of inflammatory versus antiinflammatory Th1 cell fate determination, Journal of Experimental Medicine , 2018, 215(7): 1813-1821;
Lan He , Wangpeng Gu , Meng Wang , Xiaoyan Chang , Xiaoyu Sun , Yuan Zhang , Xuan Lin , Chenghua Yan , Weiguo Fan , Pan Su , Yanming Wang , Chunyan Yi , Guomei Lin , Li Li , Yu Jiang , Junxia Lu , Chen Dong , Haikun Wang, Bing Sun* . Extracellular Matrix Protein 1 promotes follicular helper T cells differentiation and antibody production. PNAS , 2018, 115(34): 8621-8626.
Qiaoshi Lian, Jun Xu, Shanshan Yan, Min Huang*, Honghua Ding, Xiaoyu Sun, Aiwei Bi, Jian Ding*, Bing Sun* , Meiyu Geng*, Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Research , 2017, 27:784-800.
Wenshuai Wang, Xiaoyu Sun, Yanbing Li, Jinpeng Su, Zhiyang Ling, Tianlong Zhang, Fang Wang, Hong Zhang, Hualan Chen, Jianping Ding &  Bing Sun* . Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses. Nature Communications,  2016; 7: 13577 
Su Pan, Chen Sheng, Zheng Yuhan, Zhou Haiyan, Yan CH, Yu F, Zhang YG, He L, Zhang Y, Wang YM, Wu L, Wu XA, Yu BK, Ma LY, Yang ZR, Wang JH, Zhao GX , Zhu JF, Wu ZY,  Sun B* . Novel Function of Extracellular Matrix Protein 1 in Suppressing Th17 Cell Development in Experimental Autoimmune Encephalomyelitis. Journal of Immunology  2016; 197(4): 1054-1064. 
Wang Yanming, Lian QS, Yang B, Yan SS, Zhou HY, He L, Lin GM, Lian ZX, Jiang ZF,  Sun B* . TRIM30 alpha Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING. Plos Pathogens . 2015;11(6):18. 
Sha Wenwen, Mitoma H, Hanabuchi S, Bao MS, Weng LY, Sugimoto N, Liu Y, Zhang ZQ, Zhong J,  Sun B* , Liu YJ*. Human NLRP3 inflammasome senses multiple types of bacterial RNAs. PNAS. 2014; 111 (45): 16059-16064.  
OuYang Bo, Xie SQ, Berardi MJ, Zhao XH, Dev J, Yu WJ,  Sun B* , Chou JJ*. Unusual architecture of the p7 channel from hepatitis C virus.  Nature  . 2013; 498(7455):521.
Mao Kairui, Chen SZ, Chen MK, Ma YL, Wang Y, Huang B, He ZY, Zeng Y, Hu Y, Sun SH, Li J, Wu XD, Wang XR, Strober W, Chen C, MengGX,  Sun B* . Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock.  Cell Research  . 2013; 23(2):201-212.
Zhenhu Li, Yuan Zhang, Zhiduo Liu, Xiaodong Wu, Yuhan Zheng, Zhiyun Tao, Kairui Mao, Jie Wang, Guomei Lin, Lin Tian, ​​Yongyong Ji, Meiling Qin, Shuhui Sun, Xueliang Zhu, and  Bing Sun* . Extra-Cellular Matrix protein 1 controls Th2 cell egress from lymph nodes through re-expression of sphingosine 1-phosphate receptor 1. Nature Immunology.  2011; 12(2):178-85 
Zhiduo Liu, Zhenhu Li, Kairui Mao, Jia Zou, Yuan Wang, Zhiyun Tao, Guomei Lin, Lin Tian, ​​Yongyong Ji, Xiaodong Wu, Xueliang Zhu, Shuhui Sun, Weiguang Chen, Charlie Xiang and  Bing Sun*. Dec2 promotes Th2 cell differentiation by enhancing IL-2R signaling.  Journal of Immunology . 2009;183(10):6320-9
Xuexian O Yang, Pornpimon Angkasekwinai, Jinfang Zhu, Juan Peng, Zhiduo Liu, Roza Nurieva, Xikui Liu, Yeonseok Chung, Seon Hee Chang,  Bing Sun* , Chen Dong*. Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment.  Nature Immunology . 2009;10(12):1260-6
Mude Shi, Weiwen Deng, Enguang Bi, Kairui Mao, Yongyong Ji, Guomei Lin, Xiaodong Wu, Zhiyun Tao, Zhenhu Li, Xinfen Cai, Shuhui Sun, Charlie Xiang and  Bing Sun*. TRIM30a negatively regulates TLR-mediated NF-kB activation by targeting TAB2 and TAB3 for degradation. Nature Immunology . 2008;9(4):369-77. 
Wei Lu, Bojian Zheng, Ke Xu, Wolfgang Schwarz, Jiadong Cheng, Shuming Duan, Vincent Deubel,  Bing Sun * . SARS-CoV 3a protein forms an ion channel and modulates virus release.  PNAS.  2006; 103(33);12540- 12545.

Sun Bing received his PhD in Immunology from Shanghai Second Medical University in January 1991. From January 1991 to January 1994, he was a lecturer and associate professor at Shanghai Medical University. From February 1994 to January 1999, he was a postdoctoral fellow and senior visiting scholar at NIH in the United States. In 1998, he was selected as the immunology major of the "Hundred Talents Program" of the Chinese Academy of Sciences. Since February 1999, he has been in charge of basic immunology research at Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. In 2003, he was awarded the title of National Outstanding Youth and supported by the Research Fund. Since 2003, he has been a member of the Review Committee of the Immunology Professional Group of the National Natural Science Foundation of China. Since January 2005, he has been the director of the Antibody Research Center of the Institute of Biochemical Cells, Shanghai Academy of Biological Sciences, Chinese Academy of Sciences. He is currently the co-director of the Pasteur Institute in Shanghai, Chinese Academy of Sciences.

Published papers and scientific research:

He has presided over and participated in the innovation projects of the Chinese Academy of Sciences, the general and key projects of the National Natural Science Foundation of China, the National 973 Project, the key and major projects of the Shanghai Science and Technology Commission, and the Sino-German cooperation project, and participated in the Shanghai Science and Technology Commission and the Natural Science Foundation of China. and the excellent talent research team of the Chinese Academy of Sciences. He is an adjunct professor at the School of Life Sciences of the University of Science and Technology of China and the School of Medicine of Shanghai Jiaotong University. There are 15 doctoral and 10 master students. After returning to China, as the corresponding author, he has published nearly 20 SCI articles.

Once funded by NIH as a NIH researcher, Lubin Jiang was recruited to CAS "Hundred Talents Program" to cooperate with PLA's research

 Jiang Lubin

Researcher | Doctoral Supervisor

Subject apparent genetics

Research group Plasmodium Epigenetics Research Group

telephone +86 021-54923072

Mail lbjiang@ips.ac.cn

address Room B106, New Life Science Laboratory Building, No. 320, Yueyang Road, Xuhui District, Shanghai

research direction

Using the original epigenetic gene editing technology as a means to study the epigenetic regulation mechanism that mediates the immune escape and multi-path infection of Plasmodium in the pathogenesis of malaria, explore new targets for the development of malaria vaccines and antimalarial drugs, and explore malaria prevention and control. new strategies for control.

Personal profile

Jiang Lubin is a second-level researcher and deputy director of the Pasteur Institute in Shanghai, Chinese Academy of Sciences. Graduated from Nanchang University with a bachelor's degree and master's degree, and a doctorate degree from Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences. He then went to the National Institutes of Health ( NIH ), where he worked as a postdoctoral fellow and a research assistant, engaged in the research and development of malaria vaccines. Since 2012 , the Plasmodium Epigenetics Laboratory has been established at the Pasteur Institute of Shanghai, Chinese Academy of Sciences. In 2013 , he was funded by the "Hundred Talents Program" of the Chinese Academy of Sciences and was awarded "Excellent" in the final evaluation. He has successively served as Distinguished Professor of ShanghaiTech University, Executive Director of Parasitology Professional Committee of Chinese Zoological Society, and editorial board member of Chinese Journal of Parasitology and Parasitic Diseases. After returning to China, he successively presided over the National Science Fund for Distinguished Young Scholars, the National Key R&D Program "Protein Machine", the US NIH R01 Project, the National Foundation Committee ( NSFC ) -NIH China-US Key Project, the International Alliance of Science and Technology Organizations ( ANSO ) Key Project, the Chinese Academy of Sciences STS More than ten important scientific research projects such as regional key projects. He has published more than 40 SCI research papers , among which the corresponding authors are in Nature ( 2 papers), PNAS ( 4 papers), Nucleic Acids Research (1 ) and many other research papers published in international journals. A total of 6 national invention patents and international PCT patents have been applied for antimalarial drugs , of which a small molecule drug candidate has entered preclinical research. In 2019 , he was awarded the Advanced Individual of Shanghai Science and Technology System, and in 2020 , he was awarded the "Zhu Liyuehua" Award for Outstanding Teacher of the Chinese Academy of Science.

1. Deputy Director, Key Laboratory of Molecular Viruses and Immunity, Chinese Academy of Sciences ( August 2016 to present)

2. Distinguished Professor, School of Life Sciences, ShanghaiTech University ( March 2015 to present)

3. Director of the Council of Shanghai Institute of Major Infectious Diseases and Biosafety ( 2020 -present)

4. Standing member of the Parasitology Professional Committee of the Zoological Society of China ( October 2019 - October 2023 )

5. Editorial board member of "Chinese Journal of Parasitology and Parasitic Diseases" ( August 2018 - August 2023 )

6. Vice Chairman of the First Council of Artemisinin Science and Technology Alliance ( January 2019 - December 2022 )

He published paper with military scientist Yan Ding of PLA  " Discovery of Novel Plasmodium falciparum HDAC1 Inhibitors with Dual-Stage Antimalarial Potency and Improved Safety Based on the Clinical Anticancer Drug Candidate Quisinostat".

• 
  

Zhiheng Xu, funded by US NIH and recruited to Chinese Academy of Sciences "Hundred Talents Program", helped PLA establish the first animal model of Zika virus microcephaly and confirm that Zika virus can directly cause the occurrence of microcephaly

 

Xu Zhiheng Title: Researcher Tel: 86-10-64806581 (O) E-mail： zhxu@genetics.ac.cn Lab Homepage: Research direction: signal transduction and the pathophysiological mechanism of disease

Xu Zhiheng, Ph.D., researcher, doctoral supervisor

　, graduated from Shanghai Second Military Medical University in 1989, and received his Ph.D. from Rutgers University, New Jersey, USA in 1999. From 1999 to 2005, he worked as a postdoctoral fellow and senior research assistant at Columbia University, USA. Published more than 60 papers as corresponding authors, including Science, Cell Stem Cell, Nature Neuroscience, Immunity, Nature Metabolism, Nature Communications (3 papers), Cell Reports (5 papers), Cell Research (4 papers), Blood, Hepatology, Advanced Science , PNAS, J Cell Biol., PLoS Biology, Annual Review Virology, MCB (2 articles), JBC (6 articles) and other world-class journals. He has successively received Ruth L. Kirschstein National Research Service Award from NIH, Bush Fellowship and Waksman Fellowship of Rutgers University, National Science Fund for Distinguished Young Scholars, Innovation Group (Principal) of the Fund Committee, and 863 Project (Chief) funding. As well as "2019 and 2021 Chinese Academy of Sciences Outstanding Mentor Award", "Tang Lixin Teaching Famous Teacher Award", "Zhu Liyuehua Outstanding Teacher Award" and "Yihai Kerry Outstanding Teacher Award", and the first prize of Beijing Science and Technology Award.

Main research contents:

        1) Combined analysis of bioinformatics and multi-omics (single-cell sequencing, ATAC sequencing, genome, proteome, lipid metabolome, etc.), high-resolution imaging, in vivo labeling and imaging, neural lineage and Neural circuit tracing, optical and chemical genetics, and the intersection of the above-mentioned multidisciplinary techniques and molecular and cellular biology techniques, in-depth study of the molecular and cellular mechanisms of brain development.

        2) Discover new pathogenic genes, establish and use genetic manipulation mouse models to study the pathogenesis of neuropsychiatric diseases such as microcephaly, autism, schizophrenia, ALS and multiple sclerosis.

Student Awards (2012-19):

        "Excellent Doctoral Dissertation of Chinese Academy of Sciences" (2 persons); "Chinese Academy of Sciences President's Award" (4 persons); "Chinese Society of Cell Biology Outstanding Young Papers" first prize (highest level, 2 persons); "Zhang Xiangtong Outstanding Neuroscience Award" "Thesis Award"; "UCAS-BHP Billiton Scholarship"; "Li Zhensheng Scholarship" (3 persons); "Procter & Gamble Outstanding Graduate Student Award of University of Chinese Academy of Sciences"; "Hengyuanxiang Talent Award" (3 persons); "Yihai Kerry Outstanding Doctoral Student Award" " (4 people); "Diao Scholarship" first prize (2 people), etc. A doctoral student was directly employed by Xiangya Medical College of Central South University (985 University) as a distinguished professor and doctoral supervisor. Another doctoral student was hired by Fujian University (now Fujian Medical University) as a Distinguished Associate Professor (Independent Researcher).

PUBLICATIONS (* Corresponding author)  

 

1.Pang HH, Jiang YS… Xu Z*, Hu ZP* (2021) Aberrant NAD+ metabolism underlies ZIKA virus-induced microcephaly Nature Metabolism Doi: 10.1038/s42255-021-00437-0

 

2.Chang YF, Jiang YS, et al., Xu Z* (2021) Dissecting of the Gene Networks Affected by Zika Virus Infection in a Mouse Microcephaly Model. Genomics Proteomics & Bioinformatics doi.org/10.1016/j.gpb.2019.06.004 (IF:7.3)

 

3.Li C, Zheng Y, et al., Xu Z* (2021) SRPS Associated Protein WDR60 Regulates the Multipolar-to-Bipolar Transition of Migrating Neurons during Cortical Development. Cell Death & Disease. 12;12(1):75. doi: 10.1038/s41419-020-03363-3. (IF: 6.3)

 

4. Xin Tai Wang, Lin Zhou, Xinyu Cai, Fangxiao Xu, Zhiheng Xu , Xiang-Yao LI, Ying Shen (2021) Deletion of Mea6 in cerebellar granule cells impairs synaptic development and motor performance.   Frontiers in Cell and Developmental Biology doi. org/10.3389/fcell.2020.627146

 

5.Li C*, Xu D, Xu Z* (2021) The development of human antibodies against Zika virus. Zika Virus Control, Vaccines, Therapy, and Associated Conditions. Elsevier (book chapter)

 

6.Xu D*, Li C, Xu Z*(2021) Zika virus infection disrupts the development of both neurons and glial cells. Zika Virus Biology, Transmission, and Pathology. Elsevier (book chapter)

 

7.Zhao Z et al.,…Zhang XH*, Xu Z*(2020) Zika Virus Infection Leads to Variable Defects in Multiple Neurological Functions and Behaviors in Mice and Children. Advanced Science DOI:10.1002/advs.201901996 (IF:15.8)

 

8.Shohayeb B, Ho U, Yeap YY, Parton RG, Millard SS, Xu Z, Piper M, Ng DCH. (2020)The association of microcephaly protein WDR62 with CPAP/IFT88 is required for cilia formation and neocortical development. HUMAN MOLECULAR GENETICS，2020,29(2):248-263,

 

9.Zhang M, Fu Z, Li C, Liu A, Peng D, Xue F, He W, Gao S, Xu F, Xu D, Yuan L, Zhang F, Xu Z, Xu T, Xu P. Fast Super-Resolution Imaging Technique and Immediate Early Nanostructure Capturing by a Photoconvertible Fluorescent Protein. Nano Lett. 2020 Apr 8;20(4):2197-2208

 

10. Wang J, Li T, Wang JL, Xu Z, Meng W, Wu QF. (2020) Talpid3-Mediated Centrosome Integrity Restrains Neural Progenitor Delamination to Sustain Neurogenesis by Stabilizing Adherens Junctions. Cell Rep. 15;33(11):108495. doi: 10.1016/j.celrep.2020.108495.

 

11. Xu D, Li C, Qin CF, Xu Z*(2019) Update on the Animal Models and Underlying Mechanisms for ZIKV-Induced Microcephaly. Annu. Rev. Virol.  doi.org/10.1146/annurev-virology-092818-015740

 

12. Nielsen-Saines K, Brasil P, Kerin T, Vasconcelos Z, Gabaglia CR, Damasceno L, Pone M, Abreu de Carvalho LM, Pone SM, Zin AA, Tsui I, Salles TRS, da Cunha DC, Costa RP, Malacarne J, Reis AB, Hasue RH, Aizawa CYP, Genovesi FF, Einspieler C, Marschik PB, Pereira JP, Gaw SL, Adachi K, Cherry JD, Xu Z, Cheng G, Moreira ME. (2019) Delayed childhood neurodevelopment and neurosensory alterations in the second year of life in a prospective cohort of ZIKV-exposed children.  Nat Med.  25(8):1213-1217. doi: 10.1038/s41591-019-0496-1

 

13. Li H, Saucedo-Cuevas L, Yuan L, Ross D, Johansen A, Sands D, Stanley V, Guemez-Gamboa A, Gregor A, Evans T, Chen S, Tan L, Molina H, Sheets N, Shiryaev SA, Terskikh AV, Gladfelter AS, Shresta S, Xu Z, Gleeson JG. (2019).Zika Virus Protease Cleavage of Host Protein Septin-2 Mediates Mitotic Defects in Neural Progenitors. Neuron. 20;101(6):1089-1098.e4. doi: 10.1016/j.neuron.2019.01.010.

 

14. Wang XT et al., Xu Z*, Shen Y* (2019) MEA6 deficiency impairs cerebellar development and motor performance by tethering protein trafficking.  Frontiers in Cellular Neuroscience 11;13:250. doi: 10.3389/fncel.2019.00250

 

15. Xu YP, Qiu Y, Zhang B, Chen G, Chen Q, Wang M, Mo F, Xu J, Wu J, Zhang RR, Cheng ML, Zhang NN, Lyu B, Zhu WL, Wu MH, Ye Q, Zhang D, Man JH, Li XF, Cui J, Xu Z, Hu B, Zhou X, Qin CF. (2019) Zika virus infection induces RNAi-mediated antiviral immunity in human neural progenitors and brain organoids. Cell Res. 2019 Apr;29(4):265-273. doi: 10.1038/s41422-019-0152-9.

 

16. "Zika Virus and Zika Virus Disease" Chapter 10 Xu Dan, Xu Zhiheng Zika Virus and Zika Virus Disease. (2019) People's Health Publishing House

 

17. Wang S. et al., Xu Z* . (2018). Sh3rf2 haploinsufficiency leads to unilateral neuronal development deficits and autistic-like behaviors in mice.  Cell Reports DOI: 10.1016/j.celrep.2018.11.044 (Xinhua and China Science News conducted an interview report)

 

18. Zhang et al., Xu Z* (2018) cTAGE5/MEA6 Controls Brain Development through Regulation of Neuronal Trafficking of Cellular Components. PNAS doi/10.1073/pnas.1804083115

(Direct Submission Plus)

 

19. Xu D.,  Zhu Y., and Xu Z*. (2018) MEKK3 Coordinates with FBW7 to Regulate WDR62 Stability and Neurogenesis. PLoS Biology 19;16(12):e2006613. doi: 10.1371/journal.pbio.2006613

 

20. Li C et al., Xu Z*, Zhang L*. (2018). A single injection of human neutralizing antibody protects against Zika virus infection and microcephaly in the developing fetuses. Cell Reports DOI: 10.1016/j.celrep.2018.04.005

 

21. Li C et al., Xu Z*. (2018). Disruption of Glial Cell Development by Zika Virus Contributes to Severe Microcephalic Newborn Mice. Cell Discovery DOI: 10.1038/s41421-018-0042-1.

 

22. Zhu X, Li C, Afridi SK, Zu S, Xu JW, Quanquin N, Yang H, Cheng G*, Xu Z*. (2018). E90 subunit vaccine protects mice from Zika virus infection and microcephaly. Acta Neuropathol Commun. 2018 Aug 10;6(1):77. doi: 10.1186/s40478-018-0572-7. (IF: 5.4)

 

23. Zhou Y... Xu Z*, Chen ZJ*, Gao F*. (2018). Wdr62 is involved in meiotic initiation via activating JNK signaling and associated with POI in humans. PLoS Genet. 13;14(8):e1007463. doi: 10.1371/journal.pgen.1007463.

 

24. Zhang H...Xu Z, Sun T. (2018). Upregulation of MicroRNA miR-9 Is Associated with Microcephaly and Zika Virus Infection in Mice. Mol Neurobiol. 56(6):4072-4085  doi: 10.1007/s12035-018-1358-4.

 

25. Shohayeb B, Lim NR, Ho U, Xu Z, Dottori M, Quinn L, Ng DCH. (2018). The Role of WD40-Repeat Protein 62 (MCPH2) in Brain Growth: Diverse Molecular and Cellular Mechanisms Required for Cortical Development. Mol Neurobiol. 55(7):5409-5424. doi: 10.1007/s12035-017-0778-x.

 

26. Ling Y,.. Xu Z*, Qin CF*. (2017). A single mutation in the prM protein of Zika virus contributes to fetal microcephaly. SCIENCE   eaam7120, DOI: 10.1126/science.aam7120 (Previewed or highlighted by Nature, Science, Nature Reviews Neurobiology, Nature Reviews Microbiology, PNAS et al., Covered by >100 media, including New York Times, Reuters, The Washington Post, Los Angeles Times, USA Today, NBC News, NPR, The Scientist, etc. 第一完成课题组)

 

27. Fan et al., Xu Z* (2017) Mea6 Deletion in Pancreatic β Cells Impairs Proinsulin Trafficking and Insulin Biogenesis in Mice. J Cell Biology DOI: 10.1083/jcb.201705027

 

28. Wang S., Hong S... Xu Z*. (2017) Transfer of Convalescent Serum to Pregnant Mice Prevents Zika Virus Infection and Microcephaly in Offspring. Cell Research  doi:10.1038/cr.2016.144

 

29. Deng et al., Xu Z*, Qin CF*.  (2017) Intranasal infection and contact transmission of Zika virus in guinea pigs. Nat. Commun. doi:10.1038/s41467-017-01923-4

 

30. Li C, Deng Y-Q, Wang S...Xu Z*, Qin C*, Cheng G*. (2017) 25-Hydroxycholesterol protects host against ZIKV infection and its associated microcephaly. Immunity 46(3):446-456. doi: 10.1016/j.immuni.2017.02.012

 

31. Oh Y et al., Xu Z*, Jin P*, Song H., Ming G-L*, Lee G*. (2017) Zika virus directly infects human peripheral neurons and induces cell death. Nature Neuroscience 20(9):1209-1212. doi: 10.1038/nn.4612.

 

32. Zhang et al., Xu Z* (2017) American Strain of Zika Virus Causes More Severe Microcephaly than an Old Asian Strain in neonatal Mice. EBioMedicine doi: 10.1016/j.ebiom.2017.10.019.

 

33. Li C, Zhu X,. .. Xu Z*, Cheng G*. (2017) Chloroquine, a FDA-approved Drug, Prevents ZIKV Infection and its Associated Congenital Microcephaly in Mice. EBioMedicine doi:10.1016/j.ebiom.2017.09.034

 

34. Yoon KJ, et al., Xu Z*, Qian J*, Zhu H*, Song H*, Ming G-L*. (2017) NS2A protein encoded by Zika virus disrupts mammalian cortical neurogenesis. Cell Stem Cell 21(3):349-358.e6. doi: 10.1016/j.stem.2017.07.014. (*Senior author)

 

35. Wang S....Z Xu and Z Fan. (2017) Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. CELL 171(1):201-216.e18. doi: 10.1016/j.cell.2017.07.027.

 

36. Xu D.,  Zhu Y., and Xu Z*. (2017) Efficient genetic manipulation in the developing brain of tree shrew using in utero electroporation and virus infection. J Genetics and Genomics doi: 10.1016/j.jgg.2017.09.007

 

37. Li C, Xu D, .. Qin C*, Xu Z*. (2016) Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice. Cell Stem Cell doi:10.1016/j.stem.2016.04.017 (Previewed or highlighted by Science, Nature Reviews Neurobiology, Nature Reviews Microbiology; Trends in Molecular Medicine, etc. Covered by >300 media, including BBC, Reuters, Los Angeles Times, USA Today, NBC News, Fox News, The Scientist, etc. ‘Best of Cell Stem Cell 2016’)

 

38. Zhang HS…. Xu Z*. (2016) Brain-specific Crmp2 deletion leads to neuronal development deficits and behavioural impairments in mice. Nat. Commun. doi: 10.1038/ncomms11773.

 

39. Wang Y, Liu L,.. Xu Z*. (2016) Mea6 controls VLDL transport through the coordinated regulation of COPII assembly. Cell Research  doi:10.1038/cr.2016.75

 

40. Zhang F. Yu JW, Yang T. Xu D,.Xia YH., Xu Z*. (2016) A Novel c-Jun N-terminal Kinase (JNK) Signaling Complex Involved in Neuronal Migration during Brain Development. J Biol Chem pii: jbc.M116.716811. (Cover story, “Paper of the week” with editorial comments and highlight for the student)

 

41. Zhang L, Zhang F,... Xu Z*. (2016)  The B cell receptor BR3 modulates cellular branching via Rac1 during neuronal migration. J Mol Cell Biol.  pii: mjw034

 

42. Xu D. and Xu Z*. (2016) Driving WDR62 to the Pole. Cell Cycle DOI:10.1080/15384101. 2016.1154374

 

43. Shao XM. et al., (2016) Numb Regulates Vesicular Docking for Homotypic Fusion of Early Endosomes via Membrane Recruitment of Mon1b. Cell Research doi: 10.1038/cr.2016.34

 

44. Liu B…Xu Z., ZhengYF. (2016) MAZ mediates the cross-talk between CT-1 and NOTCH1 signaling during gliogenesis. Sci Reports 6:21534. doi: 10.1038/srep21534

 

45.   Liu K, Lei R, Li Q, Wang XX, Wu Q, An P, Zhang J, Zhu M, Xu Z, Hong Y, Wang F, Shen Y, Li H, Li H. (2016) Transferrin Receptor Controls AMPA Receptor Trafficking Efficiency and Synaptic Plasticity. Sci Rep. 6:21019. doi: 10.1038/srep21019

 

46.  Li P… Xu Z*, and Zhu Z*. (2015) Epigenetic silencing of microRNA-149 in cancer associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment Cell Research 25(5):588-603

 

47. Lim NR, Yeap YY, Zhao TT, Yip YY, Wong SC, Xu D, Ang CS, Xu Z, Bogoyevitch MA, Ng DC. (2015) Opposing roles for JNK and Aurora A in regulating WD40-Repeat Protein 62 association with spindle microtubules. J Cell Sci. 128:527-540

 

48. Zhang F. Xu D,. Sun YM., Xu Z*.  (2014)  Epigenetic regulation of Atrophin1 by lysine-specific demethylase is required for cortical progenitor maintenance. Nat. Commun, 5:5815. doi: 10.1038/ncomms6815

 

49. Xu D. Zhang F, Wang Y, Sun Y, Xu Z*. (2014) Microcephaly Associated Protein WDR62 Regulates Neurogenesis through JNK1 in the developmental cortex. Cell Reports 6(1):104-16

 

50. Yu J, Zhang F, Zhang Y, Fan M and Xu Z* (2014) TAK1 is activated by TGF-β signaling and controls axonal growth during brain development. J Mol Cell Biol.  6(4):349-51.

 

51. Yao M, Wang Y, Zhang P, Chen H, Xu Z, Jiao J, Yuan Z. (2014) BMP2-SMAD Signaling Represses the Proliferation of Embryonic Neural Stem Cells through YAP. J Neuroscience 34(36):12039-48

 

52. Zhu Y, Wang C, Yu M, and Xu Z*. (2013)  ULK1 and JNK are Involved in Mitophagy Incurred by LRRK2 G2019S Expression. Protein Cell 4(9): 711-21.

 

53. Shi W, Chen Y, Gan G, Ren J, Wang Q, Xu Z, Xie X, and Zhang Y. (2013) Brain tumor regulates neuromuscular synapse growth and endocytosis in Drosophila by suppressing Mad expression. J Neuroscience 24;33(30):12352-63.

 

54. Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ. (2013) HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. PNAS 19;110(12):4604-9.

 

55. Yang T., Sun YM…Xu Z* (2012) POSH Localizes Activated Rac1 to Control the Formation of Cytoplasmic Dilation of the Leading Process and Neuronal Migration. Cell Reports 2(3):640-51 (Article).

 

56.  Wilhelm M, Kukekov NV, Schmit TL, Biagas KV, Sproul AA, Gire S, Maes ME, Xu Z, Greene LA.（2012）Sh3rf2/POSHER protein promotes cell survival by ring-mediated proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty of SH3s) protein. J Biol Chem. 287(3):2247-56.

 

57. J Niu, M Yu and Z Xu*. (2012) Leucine-Rich Repeat Kinase 2 (LRRK2) Disturbs Mitochondrial Dynamics via Dynamin-Like Protein (DLP1). J NeuroChem 122(3):650-8.

 

58. J Cui, M Yu, Z Xu* (2011). Expression of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibits the Processing of uMtCK to Induce Cell Death in cell culture model system. Biosci Rep 31(5):429-437.

 

59. Y Sun, T Fei, T Yang, F Zhang, Y Chen, Z Xu* (2010) The suppression of CRMP2 expression by BMP-SMAD gradient signaling controls multiple stages of neuronal development. J Biol Chem. 285(50): 39039–39050.

 

60. Ren J., Wang Y., Liang Y....and Xu Z* (2010) Methylation of ribosomal protein s10 by protein arginine methyltransferase 5 regulates ribosome biogenesis J Biol Chem. 285(17):12695-705.

 

61. C Wang, Y Tao, Y Wang, Z Xu* Regulation of the Protein Stability of POSH and MLK Family. Protein Cell 1(9): 871–878.

 

62. Y Sun, Z Xu* (2010) Regulation of Neural Stem Cell by Bone Morphogenic Protein (BMP) Signaling During Brain Development. Frontiers in Biology 5(5):380-385.

 

63. B Lu; Y Zhai, C Wu; X Pang, Z Xu, F Sun (2010) Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. BBA-Proteins and Proteomics 804(9):1780-4.

 

64. M Zhang, Y Zhang and Z Xu* (2010) POSH is Involved in Egr-Bsk (TNF-JNK) Signaling and Embryogenesis in Drosophila. J Genetics and Genomics  37(9):605-19.

 

65. Shen Q, Qin F, Gao Z, Cui J, Xu Z, and Yang C (2009) Adenine Nucleotide Translocator Cooperates with Core Cell Death Machinery to Promote Apoptosis in Caenorhabditis elegans. Mol Cell Biol,  29(14): 3881–3893.

 

66. Jin S, Pan L, Liu Z, Wang Q, Xu Z, and Zhang Y (2009) Drosophila Tubulin-specific chaperone E functions at neuromuscular synapses and is required for microtubule network formation. Development 136(9):1571-81.

 

67. Sproul A , Xu Z and Greene L (2009) Cbl Negatively Regulates JNK Activation and Cell Death. Cell Research 19(8):950-61.

 

68. Liu S, Yu M, He Y,  Xiao L,…, and Xu Z* (2008) Melittin prevents liver cancer  cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 47(6) 1964-73.

 

69. Qiao HX, Hao CJ, Li Y, He X, Chen RS, Cui J, Xu Z*, Li W*.（2008） JNK activation mediates the apoptosis of xCT-deficient Cells. BBRC 370(4):584-8.

 

70. Sun Y, Yang T, Xu Z* (2007) The JNK Pathway and Neuronal Migration. J Genetics and Genomics  34(11): 957-965.

 

71. Wilhelm M, Kukekov NV, Xu Z, Greene LA (2007) Identification of POSH2, a novel homologue of the c-Jun N-terminal kinase scaffold protein POSH. Dev Neurosci. 29(4-5):355-62.

 

72. Wang L, Zhang Y, Li H, Xu Z, Santella RM, Weinstein IB. (2007) Hint1 Inhibits Growth and Activator Protein-1 Activity in Human Colon Cancer Cells. Cancer Res.  67(10):4700-4708.

 

73. Cui J, Zhang M, Zhang YQ, Xu Z* (2007) JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin. 28(5):601-8.

 

74. Welhelm M, Xu Z., and Greene L （2007）Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model. J Biol Chem.  282(2):1288-95. 

 

75. Xu Z.*, Sproul A., Wang WY, and Greene L. (2006) SIAH1 Interacts with the Scaffold Protein POSH to Promote JNK Activation and Apoptosis. J Biol Chem. 281(1):303-12.

 (* Corresponding author)

 

76. Kukekov, N*.,Xu Z.*, and Greene(2006) Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs.  J Biol Chem. 281(22):15517-24.

 (* Equal contribution)

 

77. Tang G, Xu Z, Goldman JE. (2006) Synergistic effects of the SAPK/JNK & the proteasome pathways on GFAP accumulation in Alexander disease. J Biol Chem. 281(50):38634-43.

 

78. Xu Z.*, Kukekov, N., and Greene L (2005) A stability-based self-amplifying feed forward loop mechanism for regulation of the apoptotic JNK pathway. Mol Cell Biol.  25(22):9949-59.

(* Corresponding author)

 

79. Xu Z.* and Greene L. (2006) Activation of the apoptotic JNK pathway through the Rac1-binding scaffold protein POSH. Methods Enzymol 406:479-89.  (* Corresponding author)

 

80. Zheng S.*, Xu Z.*¨, and Longey J. (2005) Cbl-b/Cbl regulates c-Kit receptor stability through the proteasomal pathway in mast cells. Blood 105(1):226-32.  (* Equal contribution, ¨ Corresponding author).

 

81. Hanlon SE, Xu Z, Norris DN, Vershon AK. (2004) Analysis of the meiotic role of the mitochondrial ribosomal proteins Mrps17 and Mrpl37 in Saccharomyces cerevisiae. Yeast. 21(15):1241-52.

 

82. Kim K., Kim B., Xu Z, and Kim S. (2004). Mixed lineage kinase (MLK) 3-activated p38 MAP kinase mediates TGF-Beta-induced apoptosis in hepatoma cells. J Biol Chem. 279(28):29478-84.

 

83. Xu Z., Kukekov N., and Greene LA (2003). POSH (plenty of SH3’s) Acts as a Scaffold for a Multiprotein Complex that Mediates JNK Activation in Apoptotic Death. EMBO J 15; 22(2): 252-61.

 

84. Xu Z, Maroney AC, Dobrzanski P, Greene LA (2001). The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol. 21(14): 4713-24.

 

85. Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, Xu Z, Meyer SL, Savage MJ, Greene LA, Scott RW, Vaught JL (2001). Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 276(27): 25302-8.

 

86. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA (2001). beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem. 77(1):157-64.

 

87. Xu Z., and Norris D. (1999). The SFP1 gene product of S. cerevisiae regulates G2/M transitions in the mitotic cell cycle and in response to DNA damage. Genetics 150(4): 1419-28.

Academic Lecture Preview: October 14, 2021, 14:00, Researcher Xu Zhiheng (Institute of Genetics and Developmental Biology, Chinese Academy of Sciences): Research on Brain Development and Brain Disease Mechanisms

Release time: 2021-10-11 Views: 87 times

Speaker: Researcher Xu Zhiheng

Event time: 14:00 on October 14, 2021

Venue: Tencent Conference, Conference ID: 841 345 836

Lecture Content: Brain Development and Brain Disease Mechanism Research

Speaker introduction:

Xu Zhiheng is a researcher and doctoral supervisor at the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. He is the director of the Molecular Development Center of the Institute of Genetics and Development of the Chinese Academy of Sciences, the deputy director of the State Key Laboratory of Molecular Developmental Biology; the deputy director of the Neurodevelopment and Regeneration Branch and the Child Cognitive and Brain Dysfunction Branch of the Chinese Society of Neuroscience.

He graduated from Shanghai Second Military Medical University in 1989 and received his Ph.D. from Rutgers University in the United States in 1999. From 1999 to 2005, he worked as a postdoctoral fellow and senior research assistant at Columbia University, USA. He has successively won the Ruth L. Kirschstein National Research Service Award from the NIH in the United States, the "Hundred Talents Program" of the Chinese Academy of Sciences, the "Outstanding Youth" and Innovation Group (Chief) of the Fund Committee, and the 863 Project (Chief) of the Ministry of Science and Technology.

Mainly engaged in brain development and disease mechanism research. Published more than 60 papers as corresponding authors, including Science, Cell Stem Cell, Nature Neuroscience, Immunity, Nature Metabolism, Nature Communications (3 papers), Cell Reports (4 papers), PNAS, J Cell Biology, Cell Research (3 papers), Advanced Science, PLoS Biology, Blood, Hepatology, MCB (2 papers), JBC (6 papers), Annual Review Virology and other journals. The total impact factor of papers is > 480, and the citations are > 4600 times. The results were selected into the "2017 China's Major Science, Technology and Engineering Progress"; In terms of teaching, he has successively won the "Chinese Academy of Sciences Outstanding Mentor Award" (2019, 2021), "Tang Lixin Teaching Famous Teacher Award", "Zhu Liyuehua Outstanding Teacher Award", "Lingyan Award" and "Yihai Kerry Outstanding Teacher Award".

Latest research results of Zika virus released in Beijing

Time: 2016-06-07 Font size [ large, medium and small ]

　　The research team of Xu Zhiheng, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, and the research team of Qin Chengfeng, Institute of Microbial Epidemiology, Academy of Military Medical Sciences, established the first animal model of Zika virus microcephaly and confirmed that Zika virus can directly cause microcephaly. occur. In the early morning of May 12, Beijing time, the world-class academic journal "Cell Stem Cell" published the results online.

　　On the afternoon of May 11, the Bureau of Science Communication and the Institute of Genetic Development jointly organized a press conference on this scientific research achievement. People's Daily, Xinhua News Agency, Guangming Daily, Economic Daily, China Daily, China National Radio, China Central Television, Science and Technology Daily, China Youth Daily, China News Service, Wen Wei Po, China Science News and other media participated. Han Yibo, deputy director of the Institute of Genetics and Development, presided over the press conference. Director Yang Weicai first introduced the overall situation. Researcher Xu Zhiheng and researcher Qin Chengfeng of the Academy of Military Medical Sciences then released their research results and accepted media interviews.

　　Up to now, all participating media have broadcast reports, a total of more than 10 articles. Among them, People's Daily publishes reports and pushes them through its client, Xinhua News Agency broadcasts all media reports of pictures, texts and TV, CCTV's "News Network" and "Chaowen Tianxia" columns broadcast reports, and Science and Technology Daily and China Science News are published on the front page. report.

Benzhan Zhu, selected into the "Hundred Talents Program" of the Chinese Academy of Sciences,conducted a postdoctoral research at the Linus Pauling Institute in the United States and has received NIH fund

Name: Zhu Benzhan [doctoral supervisor]Sex: MaleTitle: ResearcherTel: 62849030E-mail：bzhu@rcees.ac.cnGroup: Free Radical Chemistry and Compound Toxicology Research GroupResearch Interests: Chemical and Toxicological Synergistic Toxicity Mechanisms of Free Radicals and Transition Metal IonsAdmissions majors: Organic Chemistry, Synthesis, Computing, Mechanistic Molecular Biology, Toxicology, Genetics, Medicine

CV:

        Zhu Benzhan is a researcher and doctoral supervisor of the State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences. He received his master's degree from Lanzhou Institute of Chemistry, Chinese Academy of Sciences in 1989, and his Ph.D. degree in biochemistry from Hebrew University in Jerusalem - Hadassah Medical School in 1999. In July 1999, he conducted a postdoctoral research at the Linus Pauling Institute in the United States, and was promoted to a senior research assistant professor in July 2002. In 2006, he was selected into the "Hundred Talents Program" of the Chinese Academy of Sciences and was rated as "Excellent" in the final evaluation. In 2009, it was supported by the "Outstanding Youth Fund" of the National Foundation Committee. Mainly engaged in the synergistic toxicity mechanism of complex environmental pollutants, free radicals, transition metal ions and natural antioxidants chemistry, biochemistry and toxicology research, carried out some pioneering research work. One of the main academic achievements is the discovery of a new mechanism of toxicity, namely the formation and synergistic toxicity of lipophilic adducts; since he was selected into the "Hundred Talents Program" of the Chinese Academy of Sciences and returned to work in 2006, he has discovered a new type of Fenton that is different from the classic Fenton. ) reaction of novel hydroxyl and alkoxy radical generation mechanism: PTS carcinogenic halogenated quinone metabolites react with hydrogen peroxide to generate hydroxyl radicals, but this reaction does not depend on the presence of metal ions. This mechanism can partially explain the carcinogenicity of PTS such as polyhalophenols; a new class of carbon-centered quinone radicals was detected for the first time for the previously proposed haloquinone-mediated metal ion-independent hydroperoxide decomposition The mechanism provides the most direct and conclusive experimental evidence; a novel molecular reaction mechanism for the detoxification of polyhalogenoquinones by hydroxamic acids was discovered: an extraordinary class of Lossen rearrangements that can proceed under mild conditions, which It can occur under normal physiological conditions, and it is a two-step continuous rearrangement reaction; a new type of hydroxyl radical-dependent secondary chemiluminescence generation system has been discovered, and a new molecular mechanism of chemiluminescence has been proposed. The above systematic research results have enriched and developed the classical hydroxyl radical generation theory, made important breakthroughs in the generation mechanism of PTS radicals, and promoted and led the development of pollutant radical chemistry. Published five papers in a row (the first and corresponding author). Due to the influence on free radical chemistry and toxicology, in July 2007, he was invited to give a 50-minute conference report at the famous "Gordon Research Conference"; in October 2008, he was invited to give a presentation at the "14th International Free radical Research Conference". 30-minute conference report; relevant results were written into the textbook "Free Radicals in Biology and Medicine". In 2008, he was invited to be the editorial board member and special editor of "Science Bulletin", and in January 2009, he was invited to become the international editorial board member of Chem. Res. Toxicol., a famous toxicology journal of the American Chemical Society (2011 impact factor was 3.779). He is currently a member of the "Biological and Medical Free Radicals" of the Chinese Society of Biophysics and the professional committee of "Analytical Toxicology" of the Chinese Society of Toxicology. As the main applicant, he has received funding from the National Institutes of Health and obtained a US patent as one of the main inventors. He has received funding and awards from UNESCO, European Society of Toxicology and other organizations. He has published more than 40 papers in free radical chemistry and compound toxicology, and has been cited more than 600 times by him in the SCI online version. 

Social service:

2008 Invited to be the editorial board member and contributing editor of "Science Bulletin"

In 2009, he was invited to be the editorial board member of Chem. Res. Toxicol. "Chemical Toxicology Research", a famous toxicological journal of the American Chemical Society, and the special guest editor of "China Special Issue".

In 2009, he was elected as a member of the "Biological and Medical Free Radical Professional Committee" of the Chinese Biophysical Society

2010 Invited to be the editorial board member of "Environmental Chemistry"

In 2013, he served as the director of the Eco-Environmental Research Center of the Chinese Academy of Sciences and the Joint Institute of Environmental Science of Baptist University

Undertake scientific research projects:

1. Chinese Academy of Sciences Strategic Pilot Science and Technology Project (Class B) XDB14030100 Environmental Exposure and Health Hazard Mechanisms of Typical Pollutants
2. General Program of National Natural Science Foundation of China, 21477139, Molecular mechanism and application of chemiluminescence of halogenated aromatic hydrocarbons during advanced oxidation process 2015/01-2018/12, 950,000, research principal
3. National Natural Science Foundation of China Innovation Group Project, 21321004, Environmental Processes and Toxicological Effects of Persistent Toxic Pollutants, 2014/01-2016/12, RMB 6 million, under research, in charge
4. Key Project of National Natural Science Foundation of China, 21237005, Study on the mechanism of synergistic toxicity between organic pesticides and inorganic pesticides containing copper and zinc, 2013/01-2017/12, 3 million yuan, in research, in charge
5. National Science Foundation for Distinguished Young Scholars, 20925724, Environmental Chemistry, 2010/01-2013/12, 2 million, in research, in charge
6. General Program of National Natural Science Foundation of China, 20877081, Research on the mechanism of synergistic toxicity of organic and inorganic wood protectants, 2009/01-2011/12, 300,000, completed, presided over
7. 973 Project, 2008CB418106, Research on the mechanism of cyanobacterial blooms in large and medium-sized shallow lakes, 2008/01-2012/12, 500,000, completed, the person in charge of the sixth project
8. General Program of National Natural Science Foundation of China, 20777080, Research on the formation of metal ion-independent hydroxyl radicals and the mechanism of DNA damage, 2008/01-2010/12, 300,000, completed, presided over
9. National Natural Science Foundation of China Innovation Group Project 20921063, Forms, Environmental Processes and Toxicological Effects of Persistent Toxic Pollutants, 2008/01-2009/12, 550,000, completed, participated
10. Chinese Academy of Sciences "Hundred Talents Program" project, free radical chemistry, 2006/06-2010/05, 2 million, completed, presided over

Awards and Honors:

He has received funding and awards from NIH in the United States, UNESCO, European Society of Toxicology and Hebrew University in Israel.

Representative works:

1. Zhu B.Z., Chao X.J., Huang C.H., Li Y. (2016) Delivering the cell-impermeable DNA ‘light-switch’ Ru(II) complexes preferentially into live-cell nucleus via an unprecedented ion-pairing method. Chem. Sci
2. Mao, L., Huang, C.H., Gao, H.Y., Kalyanaraman, B., Zhu, B.Z. (2015) Intrinsic chemiluminescence generation during advanced oxidation of persistent halogenated aromatic carcinogens. Environ. Sci. Technol. 49: 7940-7947.
3. Huang, C.H.; Ren, F.R.; Shan, G.Q.; Qin, H.; Mao, L.; Zhu, B.Z. (2015) Molecular mechanism of metal-independent decomposition of organic hydroperoxides by the halogenated quinoid carcinogens and the potential biological implications. Chem. Res. Toxicol., 28, 831-837.  (Cover story)
4. Zhu B.Z., Hollenberg PF (2015) Chemical toxicology in China: A special issue. Chem. Res. Toxicol.28: 279-280. (Guest Editor’s Editorial)
5. Shan GQ, Yu A, Zhao QF, Huang CH, Zhu LY, Zhu B.Z. (2015)A combined experimental and computational investigation on the unusual molecular mechanism of Lossen rearrangement reaction activated by the carcinogenic halogenated quinones. J. Org. Chem. 80: 180-189.
6. Li Y, Huang CH, Liu YX, Mao L, Zhu B.Z. (2014) Detoxifying polyhalogenated catechols through a copper-chelating agent by forming stable and redox-inactive hydrogen-bonded complexes with an unusual perpendicular structure Chemistry-A European Journal, 20(40):13028-33.
7. Shan G, Ye M, Zhu B, Zhu L.(2013) Enhanced cytotoxicity of pentachlorophenol by perfluorooctane sulfonate or perfluorooctanoic acid in HepG2 cells. Chemosphere. 93(9):2101-7.
8. Huang, C. H.; Shan, G. Q.; Mao, L.; Kalyanaraman, B.; Qin, H.; Ren, F. R.; Zhu, B. Z. (2013) The first purification and unequivocal characterization of the radical form of the carbon-centered quinone ketoxy radical adduct. Chem. Commun. 49: 6436-6438,
9. Qin H, Huang CH, Mao L, Xia HY, Kalyanaraman B, Shao J, Shan GQ, Zhu BZ. (2013) Molecular mechanism of metal-independent decomposition of lipid hydroperoxide 13-HPODE by halogenated quinoid carcinogens. Free Radic. Biol. Med. 63，459-466.
10. Shao J, Huang CH, Kalyanaraman B, Zhu B.Z. (2013) Potent methyl oxidation of 5-methyl-2’-deoxycytidine by halogenated quinoid carcinogens and hydrogen peroxide via a metal-independent mechanism. Free Radic. Biol. Med. 60, 177-182.
11. Sheng ZG, Li Y, Fan RM, Chao XJ, Zhu B.Z. (2013) Lethal synergism between organic and inorganic wood preservatives via formation of an unusual Lipophilic ternary complex. Toxicol. Appl. Pharmacol. 266: 335-344.
12. Sheng ZG, Huang W, Liu YX, Yuan Y, Zhu B.Z. (2013) Ofloxacin induces NADPH oxidase-driven ROS accumulation via β1 integrin-EGFR-Rac1 pathway in microencapsulated chondrocytes. Toxicol. Appl. Pharmacol. 266: 74-87.
13. Sheng ZG, Tang Y, Liu YX, Zhu BZ. (2013) Bisphenol A at a low concentration boosts mouse spermatogonial cell proliferation by inducing the G protein-coupled receptor 30 expression. Toxicol. Appl. Pharmacol. 266: 335-344.
14. Zhu B.Z., Mao L., Huang C.H., Qin H., Fan R.M., Kalyanaraman B., Zhu J.G. (2012) Unprecedented hydroxyl radical-dependent two-step chemiluminescence production by polyhalogenated quinoid carcinogens and H2O2. Proc. Natl. Acad. Sci. USA 109: 16046-16051.
15. Zhu B.Z., Zhu J.G., Kalyanaraman B., Mao L. and Shan G.Q. (2010) Detoxifying polyhalogenated quinones by hydroxamic acids via an unusual double Lossen rearrangement. Proc. Natl. Acad. Sci. USA 107: 20286-20290.